Current Liabilities decreased faster than Trevi Therapeutics Inc 's Cash & cash equivalent, this led to improvement in Trevi Therapeutics Inc 's Quick Ratio to 38.05, above Trevi Therapeutics Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 9 other companies have achieved higher Quick Ratio than Trevi Therapeutics Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 51 to 115.

Explain Quick Ratio?
How much Cash & cash equivalents TRVI�s has?
What are TRVI�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/TRVI/financial-strength

https://api.csimarket.com/api/v1/companies/TRVI/fundamentals

https://api.csimarket.com/api/v1/companies/TRVI/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

TRVI Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	-10.02 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	53.6 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	38.05	Subscribe	Subscribe	Subscribe	Subscribe
TRVI's Total Ranking	# 115	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-9.92 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-6.1 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 10
Healthcare Sector	# 15
Overall Market	# 115

Quick Ratio Statistics
High	Average	Low
36.5	11.56	2.26
(Jun 30 2026)		(Mar 31 2022)

Financial Statements
Trevi Therapeutics Inc 's Current Liabilities	$ 8 Millions	Visit TRVI's Balance sheet
Trevi Therapeutics Inc 's Cash & cash equivalent	$ 299 Millions	Visit TRVI's Balance sheet
Source of TRVI's Sales		Visit TRVI's Sales by Geography

Cumulative Trevi Therapeutics Inc 's Quick Ratio

TRVI's Quick Ratio for the trailling 12 Months

TRVI Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-5.62 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	60.46 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	29.79	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3607	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-2.6 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	11.96 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to TRVI Financial Strength Comparisons >> Go to Compare TRVI Quick Ratio to its Competitors

On the trailing twelve months basis TRVI Cash & cash equivalent soared by 53.6 % in Q3 2026 year on year, while Current Liabilities decreased to $8 millions, this led to increase in in Trevi Therapeutics Inc 's Quick Ratio to 29.79, above TRVI average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 422 other companies have achieved higher Quick Ratio than Trevi Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 1376 to 3607.

Explain Quick Ratio?
How much Cash & cash equivalents TRVI�s has?
What are TRVI�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 423
Healthcare Sector	# 862
Within the Market	# 3607

trailing twelve months Quick Ratio Statistics
High	Average	Low
9.98	4.85	1.75
(Mar 31 2020)		(Sep 30 2023)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Vogenx, Inc.	97.47	$ 82.118 Millions	$ 0.842 Millions
Arca Biopharma Inc	83.92	$ 1,206.587 Millions	$ 14.377 Millions
Q32 Bio Inc	56.05	$ 289.587 Millions	$ 5.167 Millions
Rallybio Corporation	51.94	$ 90.693 Millions	$ 1.746 Millions
Enliven Therapeutics Inc	45.41	$ 884.351 Millions	$ 19.473 Millions
Trevi Therapeutics Inc	38.05	$ 299.408 Millions	$ 7.869 Millions
Minerva Neurosciences Inc	30.46	$ 76.945 Millions	$ 2.526 Millions
Contineum Therapeutics Inc	30.45	$ 244.484 Millions	$ 8.028 Millions
Latigo Biotherapeutics, Inc.	28.73	$ 401.241 Millions	$ 13.964 Millions
Amylyx Pharmaceuticals Inc	26.44	$ 768.132 Millions	$ 29.048 Millions
Climb Bio Inc	25.98	$ 205.423 Millions	$ 7.906 Millions
Prothena Corporation Public Limited Company	23.73	$ 271.368 Millions	$ 11.434 Millions
Innoviva Inc	22.67	$ 1,134.297 Millions	$ 50.030 Millions
Kailera Therapeutics Inc	21.40	$ 901.454 Millions	$ 42.116 Millions
Cryoport inc	20.47	$ 653.343 Millions	$ 31.911 Millions
Roivant Sciences Ltd	20.30	$ 5,683.045 Millions	$ 279.911 Millions
Disc Medicine Inc	19.87	$ 682.816 Millions	$ 34.360 Millions
Telomir Pharmaceuticals Inc	19.07	$ 4.516 Millions	$ 0.237 Millions
Onkure Therapeutics Inc	18.58	$ 163.305 Millions	$ 8.789 Millions
Siga Technologies Inc	17.27	$ 116.380 Millions	$ 6.738 Millions
Keros Therapeutics Inc	16.36	$ 259.464 Millions	$ 15.858 Millions
Design Therapeutics Inc	16.36	$ 208.608 Millions	$ 12.753 Millions
Palvella Therapeutics Inc	15.85	$ 236.680 Millions	$ 14.928 Millions
Avalo Therapeutics Inc	15.63	$ 392.966 Millions	$ 25.135 Millions
Bioage Labs Inc	14.91	$ 283.637 Millions	$ 19.027 Millions
Damora Therapeutics Inc	14.72	$ 528.478 Millions	$ 35.892 Millions
Protagonist Therapeutics inc	14.42	$ 800.064 Millions	$ 55.464 Millions
Praxis Precision Medicines Inc	14.20	$ 745.323 Millions	$ 52.498 Millions
Tenax Therapeutics Inc	13.61	$ 113.700 Millions	$ 8.355 Millions
Corvus Pharmaceuticals Inc	13.25	$ 204.252 Millions	$ 15.418 Millions

Date modified: 2026-11-10T07:04:44+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.